NAS10030,808+1.00%S&P7,723+0.73%GOLD$4,190+0.67%BTC$85,975−0.58%VIX16.23+6.01%live tape · as of 11:17 UTC
The Screen · Technology · Electronic Components
Ibiden Co.,Ltd.
4062.T · UNKNOWN · USD · Market cap $5.50T
Ibiden Co.,Ltd., together with its subsidiaries, manufactures and sells electronic and ceramics products in Japan, Asia, North America, and internationally.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price19,555.00 USD
Fair value17,366.48
Our investment reviews on this name
2026-09-18Read Distribution19,720.00-0.8% to today ✓
2026-07-02Read Markup17,060.00+14.6% to today ✓
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Ibiden Co.,Ltd. holds its Distribution at $19,555.00. Elevated stress, defensive posture warranted, held for 4 days.
As held on the ledger · 2026-09-23
Phase
Distribution · caution
Quantitative state
Elevated stress, defensive posture warranted, held for 4 days
Price at the screen
$19,555.00
Valuation
90.91 trailing · 63.29 forward price to earnings
Values screen
PASS
Beta
1.69
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
20.05%
Below 33%
Interest-bearing debt is just 20.0% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
3.36%
Below 33%
Cash held in interest-bearing accounts and securities is 3.4% of assets, under the one-third limit.
Pass
Receivables
39.04%
Below 49%
Money owed to the company is 39.0% of assets, under the 49% limit.
Pass
Revenue purity
0.65%
Below 5%
Only 0.7% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Ibiden Co.,Ltd. clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 20%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
Fair value range in USD, drawn from the 2026-09-23 screen. The gold marker is the market price at the same screen. The price runs 11.2% above the base estimate.
Third-party analyst targets: 17 covering, consensus Strong Buy. The average target sits +37% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The risks · The things to watch: it already moves more than the market on an average day; its business and earnings are exposed to Japan and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
4062.T trades on UNKNOWN (the company is based in Japan). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-02Distribution$19,555.00-0.8%Entry 8
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.8% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 164% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 511%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (17 analysts) rates it buy, with a mean price target of $12418.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 8.6% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 164% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 511%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (17 analysts) rates it buy, with a mean price target of $12418.
2026-08-19Markup$21,580.00+37.6%Entry 6
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 37.6% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 164% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 511%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (17 analysts) rates it buy, with a mean price target of $12418.
2026-07-19Markup$15,685.00-8.1%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 8.1% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 164% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 511%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (17 analysts) rates it buy, with a mean price target of $12418.
2026-07-18Markup$17,060.00+0.0%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 164% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 511%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (17 analysts) rates it buy, with a mean price target of $12418.
2026-07-15Markup$17,060.00+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-03Markup$17,060.00+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markup$17,060.00Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
Latest News · What the Market Is Reading on 4062.T